Ningbo Menovo Pharmaceutical Co., Ltd. provided preliminary earnings guidance for 2018. For the period, the company predicted that the net profit belonging to shareholders of the listed company will be between RMB 96.5 million and RMB 103 million, with an increase of between RMB 51.82 million and RMB 58.32 million and an increase of between 116% and 131% compared with the same period of the year before. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 53.5 million and RMB 60 million, with an increase of between RMB 19.8 million and RMB 26.3 million and an increase of between 59% and 78% compared with the same period of the year before.